






















































































































































誌に掲載された総説のconclusionでは，「The use of human 
pancreatic islets can serve as a gold standard for the 
assessment of beta-cell function in the future, as clinical 






























































WS 6 による IKK-εの阻害，SB432542による TGFβ Rを介した SMAD 3 の活性化，インスリン /IGF- 1 受容体（IR/IGF 1 R）や
GLP- 1 Rを介したシグナル，GNF7156や GNF4877による GSK- 3 βの阻害，RANK/RANKLシグナルの阻害，DYRK 1 Aの阻害，
















































胞周期のG 0 期にある．インスリン等の増殖因子はG 0









図 4   FoxM 1 /PLK 1 /CENP-A経路を介した膵β細胞量制御
（A）膵β細胞において，インスリン刺激により，ERKが FoxM 1 の核内移行を促進し，一方で PI 3 キナーゼを介したインスリン
シグナルが，Cdk 1 / 2 を介して FoxM 1 の CENP-Aおよび PLK 1 遺伝子領域への DNA結合を促進することにより，CENP-Aおよ
び PLK 1 の発現を増加させる．その結果，CENP-Aのセントロメア領域への会合が PLK 1 により増強され，有糸分裂が促進される．

























































て，米国の Integrated Islet Distribution Program（IIDP），カ
ナダのアルバータ大学Clinical Islet Laboratory（CIL），英
国オックスフォード大学の JDRF UK Islets for Basic 
Research program， ま た は ヨ ー ロ ッ パ の European 
Consortium for Islet Transplantation（ECIT）における Islets 

















り TLR 4 に非依存的に膵β細胞で S100A 8 が誘導される．膵β細胞由来
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THE INCREASING DEMAND FOR HUMAN ISLETS FOR DIABETES RESEARCH
Jun Shirakawa
Laboratory of Diabetes and Metabolic Disorders Institute  
for Molecular and Cellular Regulation (IMCR) Gunma University
　β-Cell dysfunction in type 1 and type 2 diabetes mellitus is accompanied by a progressive loss of β-cells, and 
an understanding of the cellular mechanism(s) that regulate β-cell mass will enable approaches to enhancing 
hormone secretion. In fact, over the past 10-15 years, several studies have contributed to the identification of islet 
changes associated with type 1 and type 2 diabetes mellitus. It is becoming increasingly recognized that enhancement 
of human β-cell mass is one potential approach to prevent and/or cure type 1 and type 2 diabetes mellitus. Human 
islet research is crucial to understanding the mechanisms of the regulation of β-cell mass. Whereas several reports 
have described the factor(s) that enhance β-cell mass in animal models or cell lines, promoting effective human 
β-cell mass continues to be a challenge in the field. Thus, the demand for human islets for basic research is ever 
increasing, and novel findings on human islet biology are accumulating. In this review, we discuss recent scientific 
advances, as well as methodological and experimental challenges that impact human islet quality, experimental 
outcomes, and the availability of human islets, in Japan for the treatment of diabetes mellitus.
